5-Years of Thrombolytic Treatment Experience

No statistically significant difference was found in the survival analysis for different application sites of thrombolytic therapy as emergency room, clinical service and intensive care unit (p=0.85). The ED clinicians have some concerns and differences in the experience about how intravenous (IV) t...

Full description

Saved in:
Bibliographic Details
Published inDicle tıp dergisi Vol. 50; no. 3; pp. 297 - 303
Main Authors Tuncar, Alpay, Güner, Hakan, Canbaz, Hayri, Beştemir, Atilla
Format Journal Article
LanguageEnglish
Published Diyarbakir Dicle University 01.09.2023
Subjects
Anticoagulants
Cardiovascular disease
Chronic obstructive pulmonary disease
Comorbidity
Coronary vessels
Diabetes
Emergency medical care
FDA approval
Heart attacks
Hospitals
Hypertension
Intensive care
Ischemia
Medical prognosis
Mortality
Stroke
Survival analysis
Thromboembolism
Vein & artery diseases
Turkey
Online AccessGet full text

Cover

More Information
Summary:No statistically significant difference was found in the survival analysis for different application sites of thrombolytic therapy as emergency room, clinical service and intensive care unit (p=0.85). The ED clinicians have some concerns and differences in the experience about how intravenous (IV) tissue plasminogen activator (tPA) will be administered in above-mentioned settings. [...]intravenous tissue plasminogen activator use hasn't been extensively used in the clinical practice among ED clinicians. METHODS This retrospective, non-interventional, observational study included patients aged >18 years who presented to emergency department of Training and Research Hospital with acute ischemic stroke and underwent thrombolytic therapy between January 2017 and January 2022. The inclusion criteria were age >18 years, presentation to emergency department of Training and Research Hospital, the diagnosis of acute ischemic stroke and undergoing thrombolytic therapy.
ISSN:1300-2945
1308-9889
DOI:10.5798/dicletip.l3605961